Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.
Company profile
Ticker
NOTV
Exchange
Website
CEO
Robert Leasure
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
BIOANALYTICAL SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
BAS Evansville, Inc. • BASi Gaithersburg, LLC • Bronco Research • Envigo Bioproducts, Inc. • Envigo Global Services, Inc. • Envigo Holding I, Inc. • Envigo RMS B.V., Inc. • Envigo RMS, LLC • ERPP, Inc. • Histion, LLC ...
IRS number
351345024
NOTV stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
15 May 23
8-K
Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results
11 May 23
8-K
Submission of Matters to a Vote of Security Holders
17 Mar 23
10-Q
2023 Q1
Quarterly report
14 Feb 23
8-K
Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results
13 Feb 23
DEFA14A
Additional proxy soliciting materials
27 Jan 23
DEF 14A
Definitive proxy
27 Jan 23
ARS
2022 FY
Annual report to shareholders
27 Jan 23
8-K
Departure of Directors or Certain Officers
23 Jan 23
10-K
2022 FY
Annual report
12 Jan 23
Transcripts
NOTV
Earnings call transcript
2023 Q2
11 May 23
NOTV
Earnings call transcript
2023 Q1
13 Feb 23
NOTV
Earnings call transcript
2022 Q4
10 Jan 23
NOTV
Earnings call transcript
2022 Q3
11 Aug 22
NOTV
Earnings call transcript
2022 Q2
13 May 22
NOTV
Earnings call transcript
2022 Q1
11 Feb 22
NOTV
Earnings call transcript
2021 Q4
17 Dec 21
NOTV
Earnings call transcript
2021 Q3
12 Aug 21
NOTV
Earnings call transcript
2021 Q2
8 May 21
NOTV
Earnings call transcript
2021 Q1
10 Feb 21
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 24.60 mm | 24.60 mm | 24.60 mm | 24.60 mm | 24.60 mm | 24.60 mm |
| Cash burn (monthly) | (no burn) | 1.91 mm | 4.03 mm | 30.29 mm | (no burn) | 318.17 k |
| Cash used (since last report) | n/a | 3.75 mm | 7.93 mm | 59.59 mm | n/a | 625.97 k |
| Cash remaining | n/a | 20.85 mm | 16.66 mm | -34.99 mm | n/a | 23.97 mm |
| Runway (months of cash) | n/a | 10.9 | 4.1 | -1.2 | n/a | 75.3 |
Institutional ownership, Q1 2023
40.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 71 |
| Opened positions | 12 |
| Closed positions | 20 |
| Increased positions | 26 |
| Reduced positions | 17 |
| 13F shares | Current |
|---|---|
| Total value | 36.07 bn |
| Total shares | 10.40 mm |
| Total puts | 54.40 k |
| Total calls | 42.50 k |
| Total put/call ratio | 1.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Wasatch Advisors | 1.50 mm | $6.51 bn |
| Jermyn Street Associates | 1.38 mm | $25.58 mm |
| BLK Blackrock | 1.22 mm | $5.29 bn |
| Vanguard | 1.10 mm | $4.76 bn |
| Renaissance Technologies | 773.07 k | $3.35 mm |
| Balyasny Asset Management | 753.60 k | $3.26 bn |
| Geode Capital Management | 399.07 k | $1.73 bn |
| SW Investment Management | 361.72 k | $1.57 bn |
| STT State Street | 340.69 k | $1.48 bn |
| Birch Grove Capital | 296.10 k | $2.15 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Apr 23 | Nigel Brown | Common Stock | Grant | Acquire A | No | No | 0 | 25,822 | 0.00 | 30,537 |
| 1 Apr 23 | David Landman | Common Stock | Grant | Acquire A | No | No | 0 | 25,822 | 0.00 | 25,822 |
| 1 Apr 23 | Neff R Matthew | Common Stock | Grant | Acquire A | No | No | 0 | 25,822 | 0.00 | 88,210 |
| 1 Apr 23 | Johnson Richard Allen | Common Stock | Grant | Acquire A | No | No | 0 | 25,822 | 0.00 | 97,780 |
| 1 Apr 23 | Davis Gregory Cole | Common Stock | Grant | Acquire A | No | No | 0 | 25,822 | 0.00 | 67,780 |
Press releases
Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
25 May 23
Inotiv, Inc. to Participate in May Investor Conferences
19 May 23
Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results
11 May 23
Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry
4 May 23
Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023
26 Apr 23